Viewing Study NCT06839235

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:21 PM
Ignite Modification Date: 2026-01-02 @ 5:31 PM
Study NCT ID: NCT06839235
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2025-02-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Sponsor: Arbor Biotechnologies
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Hyperoxaluria Type 1 (PH1) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PH1 View
None Primary hyperoxaluria View
None AGXT View
None CRISPR View
None Gene Editing View
None Pharmacokinetics View
None Pharmacodynamics View
None ABO-101 View
None redePHine View